Bugula neritina
| Bugula neritina | |
|---|---|
| |
| The nudibranch Diaphorodoris papillata Portmann & Sandmeier, 1960 feeding on Bugula neritina (Linnaeus, 1758) | |
| Scientific classification | |
| Kingdom: | |
| Phylum: | |
| Class: | |
| Order: | |
| Family: | |
| Genus: | |
| Species: | B. neritina
|
| Binomial name | |
| Bugula neritina | |
| Synonyms[2] | |
|
Sertularia neritina Linnaeus, 1758 (basionym) | |
Bugula neritina (commonly known as brown bryozoan or common bugula) is a cryptic species complex of sessile marine animal in the genus Bugula.[2]
It is invasive with a cosmopolitan distribution.[1]
Bugula neritina is of interest from a drug discovery perspective because its bacterial symbiont, Candidatus Endobugula sertula[3], produces the bryostatins, a group of around twenty bioactive natural products. The bryostatins are under investigation for their therapeutic potential directed at cancer immunotherapy[4][5], treatment of Alzheimer's disease[5][6], and HIV/AIDS eradication[7], due to their low toxicity and antineoplastic activity.[8]
Bugula neritina is also of interest in materials science, where it is used as a model organism in biofouling studies.[9]
References
- ^ a b "Bugula neritina (brown bryozoan)". CABI (organisation). 3 May 2013. Retrieved 14 March 2015.
- ^ a b Gordon, D. (2015). Bugula neritina (Linnaeus, 1758). In: Bock, P.; Gordon, D. (2015) World List of Bryozoa. Accessed through: World Register of Marine Species at http://www.marinespecies.org/aphia.php?p=taxdetails&id=111158 on 2015-09-02
- ^ Li, Hai; Mishra, Mrinal; Ding, Shaoxiong; Miyamoto, Michael M. (2018-08-23). "Diversity and Dynamics of "Candidatus Endobugula" and Other Symbiotic Bacteria in Chinese Populations of the Bryozoan, Bugula neritina". Microbial Ecology. 77 (1): 243–256. doi:10.1007/s00248-018-1233-x. ISSN 0095-3628. PMID 30141128.
- ^ Singh R, Sharma M, Joshi P, Rawat DS (2008). "Clinical status of anti-cancer agents derived from marine sources". Anticancer Agents Med Chem. 8 (6): 603–617. doi:10.2174/187152008785133074. PMID 18690825.
- ^ a b Ruan BF, Zhu HL (2012). "The chemistry and biology of the bryostatins: potential PKC inhibitors in clinical development". Curr Med Chem. 19 (16): 2652–64. doi:10.2174/092986712800493020. PMID 22506770.
- ^ "Bryostatin – Phase II clinical testing of a non-toxic PKC activator". Blanchette Rockefeller Neurosciences Institute (West Virginia University). Retrieved 14 March 2015.
- ^ Wender, P. A.; Kee, J.-M.; Warrington, J. M. (2008-05-02). "Practical Synthesis of Prostratin, DPP, and Their Analogs, Adjuvant Leads Against Latent HIV". Science. 320 (5876): 649–652. Bibcode:2008Sci...320..649W. doi:10.1126/science.1154690. ISSN 0036-8075. PMC 2704988. PMID 18451298.
- ^ Figuerola, Blanca; Avila, Conxita (2019-06-04). "The Understudied Phylum Bryozoa as a Promising Source of Anticancer Drugs" (Document). doi:10.20944/preprints201906.0029.v1.
{{cite document}}: Cite document requires|publisher=(help)CS1 maint: unflagged free DOI (link) - ^ Yua X, Yana Y, Gua JD (2007). "Attachment of the biofouling bryozoan Bugula neritina larvae affected by inorganic and organic chemical cues". Int Biodeterior Biodegradation. 60 (2): 81–89. doi:10.1016/j.ibiod.2006.12.003.
 | This bryozoan-related article is a stub. You can help Wikipedia by expanding it. |